Ascentage Pharma GR-ADRAAPG
13F holders, Q2 2025 (June 30)12holders +6
9new positions
3sold out
$39.37avg. 13F price*
At the end of Q2 2025, 12 institutions reported holding Ascentage Pharma GR-ADR (AAPG) in their 13F filings, up 6 from Q1 2025. 9 opened new positions and 3 sold out. The largest holders were Point72 (DIFC) Ltd ($823K), Tema ETFs LLC ($610K) and NEOS Investment Management LLC ($610K).
- Company
- Ascentage Pharma GR-ADR
- CUSIP
- 04390B105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 9 | $1.9M |
| Exits | 3 | $4.1M |
All 13F filers, Q1 2025 → Q2 2025: 52,819 shares bought and 208,236 shares sold, net −155,417 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 12 holders
| Point72 (DIFC) Ltd | 0.07% | Reduce -17.8% | 20,890 | $823K |
| Tema ETFs LLC | 0.16% | New | 15,495 | $610K |
| NEOS Investment Management LLC | 0.01% | New | 15,495 | $610K |
| HSBC Holdings PLC | 0.00% | New | 9,933 | $391K |
| UBS Group AG | 0.00% | Add +196.9% | 7,357 | $290K |
| Chevy Chase Trust Holdings, LLC | 0.00% | New | 5,753 | $227K |
| XY Capital Ltd | 0.15% | Reduce -76.2% | 5,590 | $220K |
| Morgan Stanley | 0.00% | New | 956 | $38K |
| JPMorgan Chase & Co. | 0.00% | New | 211 | $8K |
| Bell Investment Advisors, Inc | 0.00% | New | 67 | $3K |
| EverSource Wealth Advisors, LLC | 0.00% | New | 24 | $945 |
| Royal Bank of Canada | 0.00% | New | 6 | $0 |
"% of holder's portfolio" is AAPG's weight in each manager's 13F, not the share of Ascentage Pharma GR-ADR the manager owns.